Results 1 to 10 of about 219,590 (352)

Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact [PDF]

Therapeutic Advances in Medical Oncology
Background: Pembrolizumab plus chemotherapy (Pembrolizumab-CT) has been suggested as first-line treatment over pembrolizumab alone in aggressive non-small-cell lung cancer (NSCLC) with ⩾50% PDL1, but studies comparing these two strategies are lacking ...
Marine Lejeune, Eric Wasielewski, Vincent Leroy, Soraya Bordier, Arnaud Scherpereel, Alexis Cortot, Clément Gauvain   +6 more
doaj   +2 more sources

Cost-effectiveness analysis of pembrolizumab versus chemotherapy in advanced non-small cell lung cancer in China based on real-world studies [PDF]

Journal of Cancer Research and Clinical Oncology
Background Although pembrolizumab has been shown to be effective, its high price has prevented it from being widely used. Especially in the real world, the application situation is still uncertain.
Ning Wan, Chen Yang, Bing Wang, Ya Guo, ZiJian He, YaJuan Lv, LiQing Lu, Ning Yang, WeiBin Xiao, YongBang Chen, Jin Yuan, DanDan Yang, Tao Liu, WenFeng Fang, ZhuoJia Chen, WeiTing Liang   +15 more
doaj   +2 more sources

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti–PD-1–refractory Hodgkin lymphoma [PDF]

Blood Advances
: Favezelimab plus pembrolizumab had promising efficacy in anti–programmed cell death protein 1 (PD-1)–refractory classical Hodgkin lymphoma in MK-4280-003; however, the contribution of favezelimab was unclear. Here, we assessed the relative contribution
Philippe Armand, Pier Luigi Zinzani, John Timmerman, Nathalie A. Johnson, David Lavie, Kannan Thiagarajan, Brian G. Topp, Pallavi Pillai, Alex F. Herrera   +8 more
doaj   +2 more sources

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

Frontiers in Pharmacology, 2021
Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients.
Tan Chongqing, Tan Chongqing, Li Sini, Zeng Xiaohui, Peng Liubao, Peng Liubao, Peng Ye, Peng Ye, Qin Shuxia, Qin Shuxia, Wang Liting, Wang Liting, Wu Meiyu, Wu Meiyu, Wan Xiaomin, Wan Xiaomin   +15 more
doaj   +1 more source

Pembrolizumab-Induced Secondary Cholangitis: A Case Report. [PDF]

Cureus
Muhd Opandi NA, Ahmed A, Robinson E, Abdulrehman A.   +3 more
europepmc   +3 more sources

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma

IJU Case Reports, 2022
Introduction Before the approval of enfortumab vedotin, no standard treatment was available as the salvage treatment for patients with metastatic urothelial carcinoma who had failed second‐line or later pembrolizumab.
Nobutaka Nishimura, Makito Miyake, Takuto Shimizu, Akira Tachibana, Nobumichi Tanaka, Kiyohide Fujimoto   +5 more
doaj   +1 more source

Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials

Frontiers in Pharmacology, 2021
Objective: This network meta-analysis will provide a complete toxicity profile, toxicity profile, and safety ranking of immune checkpoint inhibitors (ICIs) for treatment of advanced non-small cell lung cancer (NSCLC).Methods: We found 12 phase II or III ...
Weidong Zhang, Jingjing Gu, Chunming Bian, Guanhong Huang   +3 more
doaj   +1 more source

Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma

Current Oncology, 2022
Anaplastic thyroid carcinoma (ATC) are highly aggressive malignant tumors with poor overall prognosis despite multimodal therapy. As ATC are extremely rare, no randomized controlled study has been published for metastatic disease.
Laurys Boudin, Jean-Baptiste Morvan, Juliette Thariat, Denis Métivier, Pierre-Yves Marcy, David Delarbre   +5 more
doaj   +1 more source

Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues

eLife, 2021
Although Pembrolizumab-based immunotherapy has significantly improved lung cancer patient survival, many patients show variable efficacy and resistance development.
Teresa WM Fan, Richard M Higashi, Huan Song, Saeed Daneshmandi, Angela L Mahan, Matthew S Purdom, Therese J Bocklage, Thomas A Pittman, Daheng He, Chi Wang, Andrew N Lane   +10 more
doaj   +1 more source

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Liver Cancer, 2021
Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC).
Masatoshi Kudo, Ho Yeong Lim, Ann-Lii Cheng, Yee Chao, Thomas Yau, Sadahisa Ogasawara, Masayuki Kurosaki, Naoki Morimoto, Kazuyoshi Ohkawa, Tatsuya Yamashita, Kyung-Hun Lee, Erluo Chen, Abby B. Siegel, Baek-Yeol Ryoo   +13 more
doaj   +1 more source